



SURGERY PARTNERS

Disclaimer

Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," or the negative of those terms, and similar expressions and comparable terminology intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the future financial position of Surgery Partners, Inc. and its subsidiaries (the "Company"), including financial targets, business strategy, plans and objectives for future operations and future operating results. These statements reflect the Company's current views with respect to future events and are based on assumptions and subject to risks and uncertainties. These include, without limitation, risks and uncertainties related to the following: reductions in payments from, or inability to contract with, government healthcare programs managed care organizations and private third-party payors, failure to fully integrate the operations of Surgery Partners and Legacy Symbion, changes in the regulatory, economic and other conditions of the states where our surgical facilities are located, and other factors set forth under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Report on Form 10-K for fiscal year 2015 ("10-K") filed with the Securities and Exchange Commission (the "SEC") as well as other information we file with the SEC. The Company cautions investors not to place considerable reliance on the forward-looking statements contained in this presentation. You should read the Company's annual and quarterly reports, when available, and any and all other filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements contained in this presentation speak only as of the date of the presentation, and the Company undertakes no obligation to update or revise any forward-looking statements for any reason, except as required by law. The Company's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Data and Information Contained in this Presentation

This presentation also contains estimates, projections and other information concerning the Company's industry, business and the market for its products and services, as well as data regarding market research, estimates and forecasts. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Certain data in this presentation was obtained from various external sources, and neither the Company nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither the Company nor any of its affiliates, advisers or representatives makes any representations as to the accuracy or completeness of that data or to update such data after the date of this presentation. Such data involves risks and uncertainties and is subject to change based on various factors. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of the Company or the proposed offering.

Non-GAAP Financial Measures

This presentation contains certain non-GAAP financial measures, including EBITDA and Adjusted EBITDA. A "non-GAAP financial measure" is defined as a numerical measure of a company's financial performance that excludes or includes amounts so as to be different than the most directly comparable measure calculated and presented in accordance with GAAP in the statements of income, balance sheets or statements of cash flow of the company. We present non-GAAP financial measures when we believe that the additional information is useful and meaningful to investors. Non-GAAP financial measures do not have any standardized meaning and are therefore unlikely to be comparable to similar measures presented by other companies. The presentation of non-GAAP financial measures is not intended to be a substitute for, and should not be considered in isolation from, the financial measures reported in accordance with GAAP. For additional information about our non-GAAP financial measures, and a reconciliation of certain non-GAAP financial measures to the comparable GAAP measures, see the Company's 10-K, Quarterly Reports on Form 10-Q and other information we file with the SEC.

Surgery Partners Today



Largest standalone, independent surgical services company in the United States

124 surgical facilities
across 32 states

~\$250 million combined
LTM EBITDA

~\$1.7 billion combined
LTM revenue

~\$20 million of identified
synergies with NSH deal



Expanded musculoskeletal capabilities in complex procedures as well as continuum of care breadth




Payor-focused engagement strategy to address industry needs for cost of higher acuity cases



Value proposition focused on high quality, cost effective solutions for short stay surgical procedures

National Network of Healthcare Facilities

Comprehensive Network of Outpatient Care Services



Rapidly Evolving Healthcare Market

Key trends in the increasingly dynamic U.S. Healthcare market have produced an attractive backdrop for companies focused on high quality, outpatient care

1 Value proposition of the low cost / high quality outpatient setting now well understood

2 Evolution of consumer driven healthcare continues to emerge with prevalence of high-deductible health plans and increased transparency


3 Migration towards value-based care and bundled payment model continues

4 Managed care organizations actively directing patients to the appropriate setting of care, particularly outpatient focused surgical facilities

5 Improving technology, anesthesia techniques and post-op protocols shifting complex/ higher acuity procedures into the outpatient setting

Surgery Partners' Evolution and Vision

Added capabilities, expanded network footprint, and NSH acquisition driving continued net revenue growth



Strategic Achievements

2011:

Acquired NovaMed (37 surgical facilities plus ancillary optical services)

2014:

Acquired Symbion (55 surgical facilities), significantly increasing ancillary expansion targets

2015:

Completed Initial Public Offering

2017:

Acquired NSH, strengthening position as largest independent provider of outpatient surgical services in USA

Creating a Win-Win-Win Value Proposition

A Physician-Centric Value Proposition Designed to Drive High Quality Patient Care in a Low Cost Setting



PATIENTS

- Convenient, comfortable and cost-efficient settings
- Superior clinical outcomes and increasing patient satisfaction while reducing costs



PHYSICIANS

- Flexible approach to physician engagement: employment, partnership, affiliation
- Convenient and efficient surgical facilities
- Differentiated care delivery model enhancing care coordination, quality, outcomes



PAYORS

- Outpatient care at significantly lower cost than general acute care hospitals
- OIG estimates \$12bn Medicare savings shifting outpatient surgery to an ASC setting

Investment Thesis

Highly Differentiated Outpatient Delivery Model

Traditional Growth

- ✓ Dedicated Recruitment Team
- ✓ Focused M&A Strategy
- ✓ Centralized Managed Care Contracting
- ✓ Comprehensive Supply Chain Strategy
- ✓ Facility Optimization Resources

Unique Attributes


- ✓ Multi-Specialty
- ✓ Majority-Owned
- ✓ Physician Employment Capabilities
- ✓ Diversification by Design
- ✓ Service Line Expansion Capabilities

Approximately 6% same facility growth FY17 YTD¹

Large and Growing Outpatient Services Market

Shifts in Higher Acuity Procedures Destined to Create Significant Growth Opportunity

30% of healthcare spend



Most Significant Opportunities



Complex procedures only recently becoming available in an outpatient setting represents a substantial market opportunity for Surgery Partners

Premier Musculoskeletal Platform

2x

increase in hip
revision
procedures
projected by 2026

\$7BN

annual
Medicare
spend on total
joint procedures

100 million

Adults in the
United States
with chronic
pain



Well positioned for opportunity to capture total joint procedures in an outpatient setting



Expanded network of total joint, orthopedic and spine capabilities




Front-end of industry trend toward moving high complexity cases to short stay settings

Diversified Pro Forma Business Mix

Delivers Stability and Robust Opportunity for Growth

Payor Mix


Total Revenue by Payor



- Commercial payors account for 50% of total revenue
- Limited exposure to bad debt (less than 3% of revenues)
- Limited out-of-network exposure (~3% of revenues)

Specialty Mix

Volume



- Drives stable and predictable revenue
- Provides multiple levers to grow volume and increase margins
- Allows flexibility to enter primary and secondary markets

Multiple Drivers of Organic Growth

Strong Organic / Same Facility Revenue Growth



Physician Recruitment:
Traditional Growth Avenue



Physician Practice Development:
*Employment of Physicians through
acquired or de novo Practices*



Existing Partner Practice Growth:
*New associates and utilizers
potentially on partnership path*



Service Line Expansion:
*Capture market share including
higher acuity procedures*



Managed Care Strategy:
*Contracting for competitive
pricing and best patient access*




Ancillary Services Offering:
*Continue to integrate ancillary
services into our facilities*

Surgical Market Advancement

Idaho Falls, ID Case Study – Acquired in 2010

- Recruited new physician partners, including prominent surgeons in the market
- Acquired and developed two medical oncology practices and four urgent care facilities
- Executed market advancement strategy with the development of a state-of-the-art radiation oncology facility
- Enhanced referral network with acquisition of multi-specialty physician practices
- Continue to add new higher acuity service lines

Revenue Evolution



Track Record of Accretive Acquisitions



| Year: | 2011 | 2014PF | 2017PF |
|-------------|---------|---------|----------|
| Facilities: | 49 | 102 | 124 |
| Revenue: | \$240mm | \$871mm | ~\$1.7bn |

- Establishment of strong business foundation and services platform
- NovaMed added 37 surgical facilities and ancillary optical services to the platform
- Diversified geography and specialty mix expansion opportunities


- Business diversification and services expansion focused on multi-specialty
- Symbion added 55 surgical facilities and significantly increased ancillary expansion opportunities
- Initial Public Offering effective October 1, 2015

- Complementary expansion of multi-specialty capabilities
- Diversifies footprint and expands services to broaden breath of key service line offerings
- Provides significant opportunity to further adapt to changing dynamics in healthcare by further solving for cost and quality


Financial Update

Highly Attractive Financial Profile


Cases




Revenue



Adjusted EBITDA⁽²⁾



Free Cash Flow⁽³⁾



(1) Pro forma for Symbion Acquisition.

(2) Represents EBITDA less NCI.

(3) Free Cash Flow calculated as Adj. EBITDA - Maintenance CapEx.

Q3 2017 Performance Review

Q3 Financial Performance & Trends

- Q3 2017 total revenue of \$306.3 million increased 8.4% compared to third quarter of 2016 of \$282.7 million
 - 111,674 cases; \$2,743 revenue per case
 - On a normalized basis, total revenue increased 16.7% to \$330.0 million
- On a normalized basis and including the pro forma effect of the NSH acquisition, same-facility revenues increased 2.9%
 - Same-facility case volume declined 0.3%
 - Same-facility net revenue per case increased 3.3%
- Q3 2017 normalized Adjusted EBITDA of \$43.1 million compared to third quarter of 2016 Adjusted EBITDA of \$44.7 million

YTD Financial Performance & Trends

- Total revenues year to date 2017 increased 4.9% to \$880.9 million from \$839.4 million for the same period last year
- On a normalized basis and including the pro forma effect of the NSH acquisition, same-facility revenues increased 5.7% year to date
 - Same-facility case volume increased 1.3%
 - Same-facility net revenue per case increased 4.3%

Guidance

- Including the partial year impact of the NSH acquisition, which is performing as anticipated, revenue is expected to be in the range of \$1.30 billion to \$1.33 billion and Adjusted EBITDA is expected to be in the range of \$178 million to \$185 million

Key Corporate Initiatives

Organizational Focus


- ✓ **Integrating NSH** to achieve the scale benefits of a larger more diversified organization
- ✓ Focusing efforts on **core outpatient surgical facilities** by driving performance improvements to achieve increased same-facility growth and enhanced margins
- ✓ Evaluating and completing **accretive acquisitions** of short-stay surgical facilities

Initiatives to Accelerate Same-Facility Growth

- ✓ Expanding our dedicated **recruitment** team and enhancing our marketing capabilities, including total joints
- ✓ Implementing **procurement initiatives** to improve margins by harnessing the purchasing power of the combined entities and utilizing best practices across the organization
- ✓ Leveraging **enhanced analytical tools** to fully understand, evaluate, and act on the opportunities for margin improvements across all locations and procedures

Capital Structure

Leverage⁽¹⁾




Pre- and Post-NSH Acquisition Leverage

Capitalization Table

| | | Actual |
|-------------------------------|-----------|----------------|
| (\$ in thousands) | | |
| Cash | \$ | 199.6 |
| Indebtedness: | | |
| Revolving Credit Facility | \$ | - |
| 1st Lien Term Loan | \$ | 1,290.0 |
| Total Secured Debt | \$ | 1,290.0 |
| Senior Unsecured Notes (2021) | \$ | 400.0 |
| Senior Unsecured Notes (2025) | \$ | 370.0 |
| Facility Level & Other Debt | \$ | 130.7 |
| Total Net Debt | \$ | 1,991.1 |
| Covenant EBITDA | \$ | 291.8 |
| Leverage Ratio | | 6.8x |

(1) Based on credit agreement EBITDA of \$206M as of 6/30/2017.

Creating Value for Our Shareholders



Concluding Remarks
